Trial · NCT07294677
CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL
NCT07294677, Phase 1, Phase 2, Recruiting, University of Chicago
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL. Trials, record NCT07294677. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07294677
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL
- NCT number
- NCT07294677
- Status
- Recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 104 participants, estimated
- Lead sponsor
- University of Chicago
- Conditions
- Leukemia, Lymphoma
- Interventions
- Capivasertib, Venetoclax, Rituximab, Blinatumomab, Nelarabine, mini-hyperCVD
- First posted
- 2025-12-19
- Last updated
- 2026-03-04
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety of the combination of mini-hyperCVD and venetoclax plus capivasertib [Cohort 1] | After all cohort 1 participants have completed 2 28-day cycles of study treatment | Summary of dose limiting toxicities as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5. |
| Primary | Recommended Phase 2 Dose (RP2D) of capivasertib in combination with mini-hyperCVD and venetoclax [Cohort 1] | This will be assessed after all cohort 1 participants have completed 2 28-day cycles of study treatment | The dose that dose not cause dose limiting toxicities as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5 will be identified as the RP2D. |
| Primary | Efficacy of capivasertib in combination with mini-hyperCVD and venetoclax [Cohort 2 and 3] | This will be assessed after all participants have completed treatment (an average of about 8 months) | Number of participants with complete remission (CR) with measurable residual disease (MRD) negativity |
| Secondary | Rate of clinical remission (CR) [Cohort 1] | This will be assessed after all participants have completed treatment (an average of about 8 months) | |
| Secondary | Rate of clinical remission with incomplete count recovering (CRi) [Cohort 1] | This will be assessed after all participants have completed treatment (an average of about 8 months) | |
| Secondary | Rate of CR with measurable residual disease (MRD) negativity [Cohort 1] | This will be assessed after all participants have completed treatment (an average of about 8 months) | |
| Secondary | Progression free survival [All Cohorts] | up to 10 years after treatment completion | |
| Secondary | Overall survival [Cohort 2 and 3] | up to 10 years after treatment completion | |
| Secondary | Side effects of the combination of mini-hyperCVD and venetoclax plus capivasertib [Cohort 2 and 3] | This will be assessed after all participants have completed treatment (an average of about 8 months) | Summary of dose limiting toxicities as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07294677
GET https://conductscience.org/api/trials/v1/NCT07294677/registered